Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: Dave Gore who wrote (4062)	6/11/1998 4:14:00 PM
From: Eski	Read Replies (1) \| Respond to of 8798

Another one that will start to move more on the upside BMRA, Check out the chart. Biomerica's EZ Detect(TM) Sales Should Benefit from a Report to the U.S. Congress Regarding Early Testing for Colorectal Disease NEWPORT BEACH, Calif., May 28 /PRNewswire/ -- Biomerica Inc. (Nasdaq: BMRA - news) said today that sales of one of its key products, EZ Detect(TM), should significantly benefit from a new national initiative to substantially increase the number of Americans tested for deadly colorectal cancer. EZ Dectect(TM) is a U.S. Food and Drug Administration approved home test to detect hidden blood in the stool (an early warning sign of colorectal cancer). Cancer of the colon and rectum will strike more than 131,000 Americans this year and will kill more than 56,000. It is the third leading cancer killer among both men and women. Yet, less than one-third of all Americans in the susceptible age bracket (50 and older) get tested for colorectal cancer. The new Congressional report indicated that the reasons for the low testing rate include patients' embarrassment to discuss symptoms and doctors who don't push the exams. Rep. Slaughter, who chairs a Congressional task force on women's health, said colorectal cancer is an ''equal opportunity cancer'' since national statistics show it strikes men and women about equally. The New York Congresswoman stressed she is concerned about the myth that colorectal cancer is a man's disease and said her task force is developing a national education campaign to boost testing which will be aimed at doctors and patients. Rep. Slaughter stated that ''Colorectal cancer is curable if it is detected early, and far too few Americans get tested early. Everyone age 50 and over should be tested regularly.'' The American Cancer Society (ACS), in conjunction with the Congressional report, said it and other expert groups, including the Center for Disease Control, have begun planning a national testing campaign. ''We have a greater potential to save lives from colorectal cancer than breast cancer, and we've neglected this opportunity far too long,'' said Dr. Robert Smith of the ACS. U.S. colorectal cancer screening guidelines, issued last year, say that simply taking a fecal blood test every year with an easy $6 at-home test kit could cut colorectal cancer deaths by one-third. Biomerica, Inc. of Newport Beach, California, is the manufacturer and distributor of EZ Detect(TM), a physician-recommended, simple two-minute home test to detect the presence of occult (hidden) blood in the stool, an early warning sign of colorectal cancer. ''We are delighted to offer a product which may help in playing a role in this national initiative to save thousands of Americans from a particularly devastating cancer,'' said Zackary S. Irani, Biomerica CEO. ''Our test is the simplest early detection technology currently available.'' EZ Detect(TM) is sold at chain drug stores including Walgreens, OSCO, CVS, Sav-On and through AARP (American Association of Retired Persons). BIOMERICA (Nasdaq: BMRA - news) is a global medical company devoted to developing, manufacturing and marketing advanced medical diagnostic products for the early detection of diseases. The products are used in hospitals, physician's offices and in the home for self testing. Except for historical information contained herein, the statements in this Press Release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, the continued demand for the Company's products, availability of raw materials and the state of the economy. These and other risks are described in the Company's Annual Report on From 10-KSB and in the Company's other filings with the Securities and Exchange Commission. SOURCE: Bioamerica Inc. ESKI --------------------------------------------------------------------------------